Santhera Pharmaceuticals Holding AG
SIX:SANN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Santhera Pharmaceuticals Holding AG
Operating Income
Santhera Pharmaceuticals Holding AG
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Santhera Pharmaceuticals Holding AG
SIX:SANN
|
Operating Income
-CHf50.8m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Operating Income
-$568.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-36%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Operating Income
CHf51.5m
|
CAGR 3-Years
41%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Operating Income
-CHf116.4m
|
CAGR 3-Years
47%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Operating Income
CHf8.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Operating Income
-CHf19.6m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-66%
|
CAGR 10-Years
N/A
|
|
Santhera Pharmaceuticals Holding AG
Glance View
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. The company is headquartered in Pratteln, Basel-Landschaft. The company went IPO on 2006-11-03. The firm is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
See Also
What is Santhera Pharmaceuticals Holding AG's Operating Income?
Operating Income
-50.8m
CHF
Based on the financial report for Jun 30, 2025, Santhera Pharmaceuticals Holding AG's Operating Income amounts to -50.8m CHF.
What is Santhera Pharmaceuticals Holding AG's Operating Income growth rate?
Operating Income CAGR 5Y
-30%
The average annual Operating Income growth rates for Santhera Pharmaceuticals Holding AG have been 7% over the past three years , -30% over the past five years .
